Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Heart Failure Subtypes
Study on the Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Subtypes of Heart Failure
Heart failure (HF) refers to impaired cardiac function caused by various heart diseases. Patients commonly present with dyspnea, fatigue, edema and other symptoms, ranking among the leading causes of death from cardiovascular diseases worldwide. According to World Health Organization statistics, more than 26 million people globally suffer from heart failure. The rising prevalence of aging population, hypertension, diabetes and other comorbidities continues to expand the patient population, imposing a heavy burden on families and society.
Body mass index (BMI) was traditionally adopted to assess the correlation between obesity and heart failure, yet this method has inherent limitations. The obesity paradox indicates that obese heart failure patients may achieve better recovery outcomes than those with normal weight. Additionally, BMI fails to differentiate the impacts of adipose tissues distributed in distinct anatomical sites. Advances in imaging technology have enabled accurate quantification of regional fat deposits, including epicardial adipose tissue (EAT), subcutaneous adipose tissue (SAT) and intramuscular adipose tissue (IMAT).
Domestic and international studies have verified that fat distribution exerts greater influence than total fat volume. Directly adjacent to the myocardium, EAT may secrete inflammatory mediators and induce myocardial injury. SAT produces protective bioactive substances, while its effects vary across heart failure subtypes and remain inconclusive. IMAT is correlated with reduced physical activity and poor clinical prognosis. Nevertheless, most existing researches focus solely on single-site fat tissue or specific heart failure types. Comprehensive combined analysis of cardiac, somatic and muscular adipose tissues, as well as systematic comparison among diverse heart failure subtypes, remains insufficient.
This study intends to quantify the three types of adipose tissues simultaneously, combined with cardiac structural and functional examinations, to explore their associations with heart failure. The findings are expected to facilitate precise risk stratification and individualized therapeutic strategy formulation for clinicians.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Meeting the diagnostic criteria for heart failure set forth in the 2022 ESC Guidelines: presence of typical symptoms (e.g., dyspnea, fatigue, edema, etc.) and signs (e.g., pulmonary rales, jugular venous distention, third heart sound, etc.) of heart failure;
- Undergoing both coronary computed tomography angiography (CCTA) and non-contrast chest computed tomography (CT), with image quality meeting the requirements for quantitative analysis;
- Age ≥ 18 years, with complete clinical and follow-up data, and ability to cooperate with imaging examinations and follow-up assessments.
Exclusion Criteria:
- Acute myocardial infarction occurring within 3 months prior to the imaging examination;
- Other definite structural heart diseases, including congenital heart disease, myocarditis, pericardial disease, severe valvular heart disease, etc.;
- End-stage organ diseases (hepatic/renal/pulmonary failure, active malignancy);
- Unmeasurable scan images (e.g., due to pericardial effusion or artifacts);
- Incomplete or missing clinical data.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of Major Adverse Cardiovascular Events (MACE)
Tijdsspanne: The follow-up was conducted within one month after data collection was completed.
|
Major adverse cardiovascular events (MACE), defined as the composite endpoint of all-cause death, non-fatal acute myocardial infarction, and non-fatal stroke.
|
The follow-up was conducted within one month after data collection was completed.
|
|
Proportion of Participants Experiencing Major Adverse Cardiovascular Events (MACE)
Tijdsspanne: Follow-up conducted within one month after data collection was completed.
|
Composite endpoint of all-cause death, non-fatal acute myocardial infarction, and non-fatal stroke.
|
Follow-up conducted within one month after data collection was completed.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- KS2026087
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .